The inhibitory effects of non-prostanoid prostacyclin mimetics on rat neutrophil function

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 54, Issue 5, 1996, Pages 351-360

  Wise, H ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 9 (TETRAHYDRO 2 FURYL)ADENINE; BMY 22389; BMY 42393; CICAPROST; CYCLIC AMP; FORMYLMETHIONYLLEUCYLPHENYLALANINE; FORSKOLIN; GLIBENCLAMIDE; ILOPROST; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; OCTIMIBATE; UNCLASSIFIED DRUG; [3 [4 (4,5 DIPHENYL 2 OXAZOLYL) 5 OXAZOLYL]PHENOXY]ACETIC ACID;

ANIMAL CELL; ARTICLE; CELL AGGREGATION; CONTROLLED STUDY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030036652     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(96)90049-6     Document Type: Article

References (44)

1. 2+. Biochem J 1984; 224: 629-635.
2. Wheeldon A., Vardey C. J. Characterization of the inhibitory prostanoid receptors on human neutrophils. Br J Pharmacol 1993; 108: 1051-1054.
3. Lad P. M., Goldberg B. J., Smiley P. A., Olsen C. V. Receptor-specific threshold effects of cyclic AMP are involved in the regulation of enzyme release and Superoxide production from human neutrophils. Biochim Biophys Acta 1985; 846: 286-295.
4. 1 in Atherosclerosis. Berlin: Springer Verlag, 1986: 22-31.
5. Gryglewski R. J., Salvemini D. Modulation of polymorphonuclear leukocyte function by prostaglandins and nitric oxide. In: Rubanyi G. M., Vane J., eds. Prostacyclin: New Perspectives For Basic Research And Novel Therapeutic Indications. Amsterdam: Elsevier Science Publishers, 1992: 59-92.
6. Wise H., Jones R. L. Characterization of prostanoid receptors on rat neutrophils. Br J Pharmacol 1994; 113: 581-587.
7. Meanwell N. A., Romine J. L., Seiler S. M. Non-prostanoid prostacyclin mimetics. Drugs of the Future 1994; 19: 361-385.
8. Wise H., Qian Y., Jones R. L. A study of prostacyclin mimetics distinguishes neuronal from neutrophil IP receptors. Eur J Pharmacol 1995; In press.
9. Wise H., Chow B. S. The effect of non-prostanoid prostacyclin mimetics on rat neutrophil aggregation and cyclic AMP production. Br J Pharmacol 1995; 114: 84P.
10. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-3450.
11. De Lean A., Munson P. J., Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay and physiological dose-response curves. Am J Physiol 1978; 235: E97-E102.
12. Harris D. N., Asaad M. M., Phillips M. B., Goldenberg H. J., Antonaccio M. J. Inhibition of adenylate cyclase in human blood platelets by 9-substituted adenine derivatives. J Cyclic Nucleotide Res 1979; 5: 125-134.
13. Chijiwa T., Mishima A., Hagiwara M. et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromcytoma cells. J Biol Chem 1990; 265: 5267-5272.
14. 2 -dependent mechanism which is independent of transmembrane activation of adenylate cyclase. J Biol Chem 1985; 260: 6769-6775.
15. + permeability in the smooth muscle cells of the canine carotid artery. Eicosanoids 1989; 2: 213-222.
16. Jackson W. F., König A., Dambacher T., Busse R. Prostacyclin-induced vasodilation in rabbit heart is mediated by ATP-sensitive potassium channels. Am J Physiol 1993; 264: H238-H243.
17. + channels in cardiac muscle by the sulphonylurea drug glibenclamide. J Pharmacol Exp Ther 1992; 261: 540-545.
18. Marone G., Thomas L. L., Lichtenstein L. M. The role of agonists that activate adenylate cyclase in the control of cAMP metabolism and enzyme release by human polymorphonuclear leukocytes. J Immunol 1980; 125: 2277-2283.
19. Harvath L., Robbins J. D., Russell A. A., Seamon K. B. cAMP and human neutrophil chemotaxis. J Immunol 1991; 146: 224-232.
20. Coleman R. A., Smith W. L., Narumiya S. International Union of Pharmacology classification of prostanoid receptors: Properties, distribution and structure of the receptors and their subtypes. Pharmacol Rev 1994; 46: 205-229.
21. Hébert R. L., Regnier L., Peterson L. N. Rabbit cortical collecting ducts express a novel prostacyclin receptor. Am J Physiol 1995; 268: F145-F154.
22. Watanabe T., Yatomi Y., Sunago S. et al. Characterization of prostaglandin and thromboxane receptors expressed on a megakaryoblastic leukemia cell line, MEG-01s. Blood 1991; 78: 2328-2336.
23. 2+ concentration in the human erythroleukemia cell line, HEL, via pertussis toxin-insensitive G-proteins. Eicosanoids 1992; 5: S10-S12.
24. Vassaux G., Gaillard D., Aihaud G., Négrel R. Prostacyclin is a specific effector of adipose cell differentiation. J Biol Chem 1992; 267: 11092-11097.
25. Oka M., Negishi M., Nishigaki N., Ichikawa A. Two types of prostacyclin receptor coupling to stimulation of adenylate cyclase and phosphatidylinositol hydrolysis in a cultured mast cell line, BNu-2c13 cells. Cell Signal 1993; 5: 643-650.
26. Katsuyama M., Sugimoto Y., Namba T. et al. Cloning and expression of a cDNA for the human prostacyclin receptor. FEBS Lett 1994; 344: 74-78.
27. Namba T., Oida H., Sugimoto Y. et al. cDNA cloning of a mouse prostacyclin receptor. J Biol Chem 1994; 269: 9986-9992.
28. Armstrong R. A., Talpain E. Comparison of the prostaglandin E (EP) receptor of human neutrophils and HL-60 cells differentiated with DMSO. Prostaglandins 1994; 48: 221-234.
29. Seiler S., Brassard C. L., Arnold A. J., Meanwell N. A., Fleming J. S., Keely S. L. Jr. Octimibate inhibition of platelet aggregation: Stimulation of adenylate cyclase through prostacyclin receptor activation. J Pharmacol Exp Ther 1990; 255: 1021-1026.
30. Merritt J. E., Hallam T. J., Brown A. M. et al. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor. Br J Pharmacol 1991; 102: 251-259.
31. Seiler S. M., Brassard C. L., Federici M. E. et al. 2-[3-[2-(4,5-Diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid (BMY 42393): a new, structurally-novel prostacyclin partial agonist: 1) inhibition of platelet aggregation and mechanism of action. Thromb Res 1994; 74: 115-123.
32. Nielson C. P., Vestal R. E., Sturm R. J., Heaslip R. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol 1990; 86: 801-808.
33. i. Naunyn-Schmiedeberg's Arch Pharmacol 1991; 344: 682-690.
34. Bevilacqua M., Vago T., Baldi G., Renesto E., Dallegri F., Norbiato G. Nimesulide decreases Superoxide production by inhibiting phosphodiesterase type IV. Eur J Pharmacol 1994; 268: 415-423.
35. Torphy T. J. β-Adrenoceptors, cAMP and airway smooth muscle relaxation: challenges to the dogma. Trends Pharmacol Sci 1994; 15: 370-374.
36. Parramón M., González M. P., Oset-Gasque M. J. A reassessment of the modulatory role of cyclic AMP in catecholamine secretion by chromaffin cells. Br J Pharmacol 1995; 114: 517-523.
37. Derian C. K., Santulli R. J., Rao P. E., Solomon H. F., Barrett J. A. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. J Immunol 1995; 154: 308-317.
38. Schmeichel C. J., Thomas L. L. Methylxanthine bronchodilators potentiate multiple human neutrophil functions. J Immunol 1987; 138: 1896-1903.
39. Quilliam L. A., Mueller H., Bohl B. P. et al. RaplA is a substrate for cyclic AMP-dependent protein kinase in human neutrophils. J Immunol 1991; 147: 1628-1635.
40. Johnson M., Sindi H., Hussain A. et al. Inhibition of chemotactic peptide-induced neutrophil Superoxide release by theophylline, rolipram and isoprenaline is reduced by protein kinase A antagonist H89. Br J Pharmacol 1995; 114: 29P.
41. Talpain E., Armstrong R. A., Coleman R. A., Vardey C. Characterization of the PGE receptor subtype mediating inhibition of Superoxide production in human neutrophils. Br J Pharmacol 1995; 114: 1459-1465.
42. 2: relationship to cyclic AMP. Proc 9th Int Conf on Prostaglandins and Related Compounds. Adv Prostaglandin Thromboxane Leukot Res 1994; 22: In press.
43. Murray K. J. Cyclic AMP and mechanisms of vasodilation. Pharmacol Ther 1990; 47: 329-345.
44. Miller C. A., Barnette M. S., Ormsbee H. S. III, Torphy T J. Cyclic nucleotide-dependent protein kinases in the lower esophageal sphincter. Am J Physiol 1986; 251: G794-G803.